HighTower Advisors LLC Takes Position in Lexaria Bioscience Corp. (NASDAQ:LEXX)

HighTower Advisors LLC purchased a new position in shares of Lexaria Bioscience Corp. (NASDAQ:LEXX) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 13,023 shares of the company’s stock, valued at approximately $40,000. HighTower Advisors LLC owned 0.08% of Lexaria Bioscience as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, Armistice Capital LLC bought a new position in shares of Lexaria Bioscience in the second quarter valued at $2,836,000. Institutional investors and hedge funds own 13.06% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Lexaria Bioscience in a research note on Monday, December 2nd.

Insiders Place Their Bets

In other Lexaria Bioscience news, CEO Richard Christopher bought 22,828 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was purchased at an average price of $2.24 per share, for a total transaction of $51,134.72. Following the completion of the transaction, the chief executive officer now directly owns 22,828 shares of the company’s stock, valued at $51,134.72. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 26.40% of the company’s stock.

Lexaria Bioscience Stock Up 7.2 %

Shares of LEXX stock opened at $2.37 on Friday. The company has a 50 day moving average of $2.31 and a 200-day moving average of $2.84. Lexaria Bioscience Corp. has a 12-month low of $1.20 and a 12-month high of $6.85. The firm has a market cap of $41.36 million, a P/E ratio of -5.04 and a beta of 0.99.

Lexaria Bioscience Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.